Panacea Life Sciences Holdings Inc · OTC:PLSH
Panacea Life Sciences — Exactus — Investor Presentation (January 2019)
13 slides from Panacea Life Sciences's investor presentation, Jan 24, 2019
Slide 1: From the Seed to Final Product
=~ FROM THE SEED TO FINAL PRODUCT OTCQB: EXDI January, 2019
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets for future development and/or otherwise are not statements of historical fac
Slide 3: Corporate Overview
CORPORATE OVERVIEW Operating Focus + Hemp-Based CBD Consumer Products + Agriculture Sciences * Medical Devices OTC-QB: EXDI + Current with all filings @ &© * 700m shares authorized + Fully diluted shares outstanding: 18,463,915 (post split) DISS. © date of 1:8 reverse split: Effective 20 days follow
Slide 4: USA Hemp/CBD Market Opportunity
USA HEMP/CBD MARKET OPPORTUNITY $367M eh 2017 — Sales of $367M and 2018 — Hemp derived CBD The US market for Hemp represents a expected to be >$500M in 2018* ‘outpacing cannabis derived CBD massive opportunity to early movers and innovators al ~60% The Brightfield Group estimates the total CBD marke
Slide 5: The Exactus Advantage
THE EXACTUS ADVANTAGE 7 3 Agricultural technology focused Focus on developing and selling Hemp Master Development + Vertically integrated through commercialization derived products and Supply Agreement to consumer product * Full spectrum whole plant extract used in all our + Partnered with Ceed2Med,
Slide 6: Industrial hemp derived phyto-cannabinoid rich products
Industrial hemp derived phyto-cannabinoid rich products Full spectrum whole plant extract (entourage effect from full !4zl/| spectrum cannabidiol oil + pure 99% crystalline cannabidiol) THC-FREE Tinctures Edibles Capsules Topical solutions ‘Animal health Vape cartridges EXACEUS
Slide 7: Exclusive Manufacturing and Development Partnership
EXCLUSIVE MANUFACTURING AND DEVELOPMENT PARTNERSHIP All Stages of Production to the highest cGMP, food grade standards * Ability to tack and trace every unit back to the farm via integrated QR scan + Seed to sale chain of custody * Product liability insurance =f Multi year Master Supply and Developm
Slide 8: Seed to Sale Tracking
SEED TO SALE TRACKING Manufacturing Certified Genetics Extraction ae Cultivation @) Fb. Transportation id ® Harvest EXACHUS EXD
Slide 9: Investment Highlights
INVESTMENT HIGHLIGHTS = |p Leading the development of and exceeding current 2.0] industry standards Highest quality products on the market * Patented formulation technology A Healthcare and professional focused, “high-end” sales call strateey + Premann pie and aorta Master Product Development and Su
Slide 10: Management and Advisors
MANAGEMENT AND ADVISORS 8% PHILIP J YOUNG CHAIRMAN AND CEO. 20+ years Executive Management, CEO of public Biotech/Pharma Companies Built Commercial teams and managed product launches of >$300M Exits created Value of >$900MM_ ‘$200M+ in Capital Raises EMILIANO ALO! SENIOR ADVISOR Co-founder of Ceed2M
Slide 11: 2019 Milestones
2019 MILESTONES Product development Complete FDA and sales channel Initiate FDA path regulatory Qi, 2019 expansion Q2, 2019 for GRAS labeling Q3, 2019 readiness review Ceed2Med asset Q1, 2019 Complete the Q2, 2019 Upon eligibility Q4, 2019 purchase build out of the seek NASDAQ. agreement commercial
Slide 12: Summary
SUMMARY OTCQB listed, NASDAQ uplisting planned >60 SKU's currently available Immediate revenue potential Executed Master Product Development and Supply Agreement Full contro! over all aspects of the product lifecycle * Seed to final product tracking and accountability + Highest standards throughout
Slide 13: From The Seed To The Final Product
From The Seed To The Final Product Only The Highest Standards Leading The Way Raising The Bar For further information contact: PHILIP YOUNG, CEO Email pyou TIM RYAN, EVP Email t actusinc.com Phone 646.342.6199